Globally, cardiovascular diseases (CVDs) constitute one of the main causes of death. The data supporting community pharmacist interventions to lower cardiovascular events and associated mortality as well as enhance the management of CVD risk factors is examined in this article. We critically evaluate and summarize a variety of systematic reviews and important randomized controlled trials. One of the main findings is that, possibly as a result of various difficulties, very few trials examine clinical outcomes directly. On the other hand, a large body of high-quality research indicates that major CVD risk factors such hypertension, dyslipidemia, tobacco use, and increased hemoglobin A1c can be improved. Given the diversity of the therapies that were tested and the wide range of implementation contexts, care should be used when interpreting meta-analyses. In developing nations, where the majority of the world's CVD burden will soon be felt, it is crucial to produce evidence supporting pharmacist interventions. Future studies may be able to gather clinical outcomes data more frequently due to an increasing capability for clinical registry trials and data linking.